Peripheral Neuritis Treatment Market Revenue Growth Expected to Reach $2.44 Billion by 2030 with 4.8% CAGR

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Peripheral Neuritis Treatment Market By The End Of 2030?

The peripheral neuritis treatment market has demonstrated strong expansion in recent years. It is anticipated to increase from $1.93 billion in 2025 to $2.03 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.0%. The historical growth in this market can be ascribed to elements such as the high prevalence of diabetic neuropathy, the limited range of targeted therapies available, a dependence on conventional analgesics and anticonvulsants, increasing awareness of peripheral neuritis symptoms, and a fragmented healthcare infrastructure.

The peripheral neuritis treatment market size is anticipated to experience consistent expansion over the upcoming years. It is projected to achieve a valuation of $2.44 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.8%. This growth during the forecast period is primarily driven by progress in pharmacological treatments, the increasing embrace of non-pharmacological interventions like TENS and acupuncture, a greater utilization of online and retail pharmacies, a heightened emphasis on lifestyle and dietary adjustments, and the expansion of diabetic care initiatives and specialized clinics. Significant trends foreseen in this period encompass the growing adoption of AI-based peripheral neuritis monitoring tools, the rising integration of digital health platforms for managing peripheral neuropathy, the broader application of genomic and precision medicine approaches in peripheral neuritis, the increased deployment of IoT-enabled patient monitoring devices, and the accelerated development of smart manufacturing processes for peripheral neuritis therapeutics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21254&type=smp

What Primary Drivers Are Shaping The Development Of The Peripheral Neuritis Treatment Market?

The peripheral neuritis treatment market is anticipated to expand due to the escalating incidence of diabetes. Diabetes is a long-term medical condition occurring when the body fails to properly manage blood sugar (glucose) concentrations. The increasing occurrence of diabetes is attributed to factors like inactive lifestyles, poor diets, obesity, an aging demographic, and genetic predispositions. Peripheral neuritis treatment provides support to diabetic individuals by easing nerve discomfort, lessening inflammation, and boosting nerve function, which helps improve their quality of life and avert complications. For example, in 2024, the International Diabetes Federation, a Belgium-based diabetes research organization, reported that the worldwide population of adults aged 20 to 79 years afflicted with diabetes is predicted to grow substantially from around 589 million in 2024 to 853 million by 2050, indicating a 45% increase. Therefore, the rising prevalence of diabetes is a significant factor driving the growth of the peripheral neuritis treatment market.

Which Segment Classifications Shape The Peripheral Neuritis Treatment Market?

The peripheral neuritis treatment market covered in this report is segmented –

1) By Treatment Type: Pharmacological Therapies, Non Pharmacological Therapies

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

3) By Application: Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, Other Applications

Subsegments:

1) By Pharmacological Therapies: Pain Relievers (Analgesics), Antidepressants, Anticonvulsants, Topical Medications

2) By Non-Pharmacological Therapies: Physical Therapy, Transcutaneous Electrical Nerve Stimulation (TENS), Acupuncture, Lifestyle And Dietary Modifications

How Are Trends Transforming The Peripheral Neuritis Treatment Market Landscape?

Leading firms in the peripheral neuritis treatment market are concentrating on creating advanced therapies, including magnetic peripheral nerve stimulation (mPNS) treatment, to improve nerve regeneration and alleviate neuropathic discomfort. Magnetic peripheral nerve stimulation (mPNS) treatment is defined as a non-invasive neuromodulation method employing magnetic fields to stimulate peripheral nerves, thereby assisting in pain management, promoting nerve regeneration, and enhancing motor capabilities in conditions like neuropathy and musculoskeletal ailments. As an illustration, in January 2024, Neuralace Medical Inc., an American medical equipment manufacturer, unveiled Axon Therapy (mPNS) for chronic painful diabetic neuropathy (PDN), which received approval from the US government agency, the Food and Drug Administration. This particular therapy offers a rapid, pain-free, and non-invasive solution for pain alleviation. Clinical studies showed a 72.3% responder rate by Day 30 and an 81.4% responder rate by Day 90, underscoring its efficacy in diminishing pain and numbness. This endorsement signifies a substantial breakthrough in pain management, providing patients with an alternative to conventional therapies free from medication-related side effects.

Which Companies Are Expanding Their Footprint In The Peripheral Neuritis Treatment Market?

Major companies operating in the peripheral neuritis treatment market are Pfizer Inc., Johnson & Johnson (J&J), AstraZeneca Plc, Novartis AG, GSK plc, Takeda Pharmaceuticals & Co. Ltd., Eli Lilly and Co., Mallinckrodt Pharmaceuticals plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr Reddys Laboratories Ltd., Cipla Inc., Amneal Pharmaceuticals LLC, Lupin Ltd., Daiichi Sankyo Co. Ltd., Glenmark Pharmaceuticals Ltd., Cadila Pharmaceuticals Ltd.

Read the full peripheral neuritis treatment market report here:

https://www.thebusinessresearchcompany.com/report/peripheral-neuritis-treatment-global-market-report

How Does The Peripheral Neuritis Treatment Market Perform Across Major Global Regions?

North America was the largest region in the peripheral neuritis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral neuritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Peripheral Neuritis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21254&type=smp

Browse Through More Reports Similar to the Global Peripheral Neuritis Treatment Market 2026, By The Business Research Company

Peripheral Nerve Injuries Global Market Report

https://www.thebusinessresearchcompany.com/report/peripheral-nerve-injuries-global-market-report

Neurostimulation Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/neurostimulation-devices-global-market-report

Spinal Cord Stimulation Global Market Report

https://www.thebusinessresearchcompany.com/report/spinal-cord-stimulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795